Amalgamated Bank Cuts Stake in Balchem Co. (NASDAQ:BCPC)

Amalgamated Bank reduced its position in Balchem Co. (NASDAQ:BCPC) by 3.4% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 9,558 shares of the basic materials company’s stock after selling 334 shares during the quarter. Amalgamated Bank’s holdings in Balchem were worth $1,682,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also bought and sold shares of the company. QRG Capital Management Inc. grew its holdings in Balchem by 16.3% in the third quarter. QRG Capital Management Inc. now owns 5,186 shares of the basic materials company’s stock worth $913,000 after purchasing an additional 728 shares during the last quarter. Conestoga Capital Advisors LLC lifted its stake in shares of Balchem by 1.8% during the third quarter. Conestoga Capital Advisors LLC now owns 1,175,569 shares of the basic materials company’s stock worth $206,900,000 after buying an additional 20,360 shares during the period. Congress Asset Management Co. lifted its stake in shares of Balchem by 12.4% during the third quarter. Congress Asset Management Co. now owns 301,440 shares of the basic materials company’s stock worth $53,053,000 after buying an additional 33,373 shares during the period. First Trust Direct Indexing L.P. lifted its stake in shares of Balchem by 12.5% during the third quarter. First Trust Direct Indexing L.P. now owns 1,589 shares of the basic materials company’s stock worth $280,000 after buying an additional 177 shares during the period. Finally, Argent Capital Management LLC lifted its stake in shares of Balchem by 15.3% during the third quarter. Argent Capital Management LLC now owns 4,185 shares of the basic materials company’s stock worth $737,000 after buying an additional 556 shares during the period. 87.91% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several equities research analysts have recently commented on the stock. HC Wainwright lifted their price objective on shares of Balchem from $185.00 to $190.00 and gave the stock a “buy” rating in a research note on Monday, November 4th. StockNews.com upgraded shares of Balchem from a “hold” rating to a “buy” rating in a research note on Monday, October 28th.

Balchem Trading Down 1.6 %

NASDAQ BCPC opened at $178.33 on Wednesday. The company has a market capitalization of $5.80 billion, a PE ratio of 47.94, a P/E/G ratio of 5.36 and a beta of 0.65. The company has a fifty day moving average of $172.33 and a 200 day moving average of $164.99. Balchem Co. has a 1 year low of $117.10 and a 1 year high of $186.03. The company has a debt-to-equity ratio of 0.21, a current ratio of 2.98 and a quick ratio of 1.90.

About Balchem

Balchem Corporation develops, manufactures, and markets specialty performance ingredients and products for the nutritional, food, pharmaceutical, animal health, medical device sterilization, plant nutrition, and industrial markets worldwide. It operates through three segments: Human Nutrition and Health, Animal Nutrition and Health, and Specialty Products.